High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon‐α2b for 60 weeks

Hepatology

Volumn 19, Issue 2, 1994, Pages 280-285

  Reichard, Olle ^a   Foberg, Ulla ^b   Frydén, Aril ^b   Mattsson, Lars ^b   Norkrans, Gunnar ^c   Sönnerborg, Anders ^d   Wejstål, Rune ^c   Yun, Zhi‐Bing ^d   Weiland, Ola ^b  

^a DANDERYD HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d Central Microbiological Laboratory of the Stockholm County Council ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS C ANTIBODY; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; GRANULOCYTOPENIA; HAIR LOSS; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; IMMUNOBLOTTING; INFLUENZA; LIVER BIOPSY; MALE; MYALGIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VIREMIA; VIRUS REPLICATION;

ADULT; AGED; ALANINE TRANSAMINASE; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS ANTIBODIES; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMAN; IMMUNOBLOTTING; INTERFERON ALFA-2B; MALE; MIDDLE AGE; RNA, VIRAL; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TREATMENT OUTCOME; VIREMIA;

EID: 0028012650     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.1840190204     Document Type: Article

References (23)

1. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double‐blind, placebo‐controlled trial
2. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial
3. A randomized controlled open study of interferon alpha‐2b treatment of chronic non‐A, non‐B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies
4. Interferon for non‐A, non‐B chronic hepatitis. A meta‐analysis of randomised clinical trials
5. Isolation of a cDNA clone derived from a blood‐borne non‐A, non‐B viral hepatitis genome
6. Hepatitis C viral RNA in serum of patients with chronic non‐A, non‐B hepatitis: detection by the polymerase chain reaction using multiple primer sets
7. Hepatitis C virus RNA in blood donor sera detected by the polymerase chain reaction: comparison with supplementary hepatitis C antibody assays
8. Detection of hepatitis C virus (HCV) RNA by PCR related to HCV antibodies in serum and liver histology in Swedish blood donors
9. Decrease in serum hepatitis C viral RNA during alpha‐interferon therapy for chronic hepatitis C
10. Detection of hepatitis C virus RNA by nested polymerase chain reaction in sera of patients with chronic non‐A, non‐B hepatitis treated with interferon
11. Antiviral therapy of hepatitis C–present and future
12. An escalating dose regime of recombinant interferon‐alpha 2A in the treatment of chronic hepatitis C
13. Long‐term follow‐up of chronic post‐transfusion non‐A, non‐B hepatitis: clinical and histological outcome
14. Acute and chronic hepatitis revisited
15. Long‐term follow‐up of patients with chronic hepatitis C treated with alfa‐interferon
16. Hepatitis C viraemia and liver disease in symptom‐free individuals with anti‐HCV
17. Detection of hepatitis C virus by polymerase chain reaction and response to interferon‐alfa therapy: relationship to genotypes of hepatitis C virus
18. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients
19. Comparison of 1 or 3 MU of interferon alfa‐2b and placebo in patients with chronic non‐A, non‐B hepatitis
20. Interferon alpha‐2b treatment of chronic posttransfusion non‐A, non‐B/C hepatitis: long‐term outcome and effect of increased interferon doses in non‐responders
21. Autoimmunity after alpha‐interferon therapy for malignant carcinoid tumors